Celldex Therapeutics, Inc. (NASDAQ:CLDX) saw a significant decrease in short interest in the month of September. As of September 29th, there was short interest totalling 7,177,400 shares, a decrease of 42.3% from the September 15th total of 12,438,468 shares. Approximately 5.6% of the shares of the company are sold short. Based on an average daily volume of 1,772,046 shares, the short-interest ratio is presently 4.1 days.

Celldex Therapeutics (NASDAQ:CLDX) opened at 3.10 on Friday. Celldex Therapeutics has a 52-week low of $2.20 and a 52-week high of $5.02. The company’s market capitalization is $397.86 million. The firm has a 50-day moving average of $2.72 and a 200 day moving average of $2.78.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.05. Celldex Therapeutics had a negative net margin of 1,318.94% and a negative return on equity of 51.87%. The firm had revenue of $3.83 million during the quarter, compared to analysts’ expectations of $1.21 million. During the same period in the previous year, the business posted ($0.32) EPS. The business’s revenue was up 175.5% compared to the same quarter last year. Equities analysts predict that Celldex Therapeutics will post ($1.04) earnings per share for the current fiscal year.

CLDX has been the topic of a number of research analyst reports. Zacks Investment Research upgraded shares of Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price objective on the stock in a research report on Tuesday, July 11th. Aegis restated a “buy” rating on shares of Celldex Therapeutics in a research report on Thursday, June 29th. HC Wainwright set a $10.00 price objective on shares of Celldex Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 9th. Cantor Fitzgerald restated a “buy” rating and set a $9.00 price objective on shares of Celldex Therapeutics in a research report on Tuesday, September 26th. Finally, ValuEngine downgraded shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. Celldex Therapeutics currently has an average rating of “Hold” and an average target price of $5.88.

Several institutional investors and hedge funds have recently bought and sold shares of CLDX. Raymond James Financial Services Advisors Inc. lifted its stake in shares of Celldex Therapeutics by 26.2% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 28,885 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 6,000 shares during the period. BB&T Securities LLC acquired a new position in shares of Celldex Therapeutics in the 2nd quarter valued at $117,000. Voya Investment Management LLC lifted its stake in shares of Celldex Therapeutics by 17.4% in the 2nd quarter. Voya Investment Management LLC now owns 50,535 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 7,499 shares during the period. Overbrook Management Corp acquired a new position in shares of Celldex Therapeutics in the 2nd quarter valued at $139,000. Finally, Pacad Investment Ltd. acquired a new position in shares of Celldex Therapeutics in the 2nd quarter valued at $150,000. Hedge funds and other institutional investors own 56.69% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/10/13/celldex-therapeutics-inc-cldx-short-interest-down-42-3-in-september.html.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.